Kerecis' patent pending Marigen™ Lipid Enhanced Matrix is a unique marine-derived tissue regeneration product. Marigen™ tissue regeneration technology is used in our products to treat chronic wounds and for abdominal wall reconstruction. Current tissue products are based on tissue of human and porcine origin. Marigen uniquely is derived from fish skin, offering not only improved economics and clinical performance but also reduced disease transfer risk and absence of cultural constraints on usage.

KERECIS FOCUSES ON TWO HIGH GROWTH MARKETS

About 1.4 million hernia repair operations are performed globally annually. A hernia is a defect in the abdominal wall through which the internal organs may protrude with only the skin as a cover. Complications may arise post-operatively, including rejection of the mesh that is used to repair the defect. Kerecis provides a unique abdominal wall reconstruction material that is re-vascularized and provides strong repair hold, a promise for patients with challenging hernias.

Every year about 34.5 million chronic wounds are treated globally. Kerecis is committed to the prevention and treatment of chronic wounds - that often are the consequence of diabetes and circulation complications. Chronic wounds cause patients severe emotional and physical stress and create a significant financial burden on patients and the whole healthcare system. In the chronic wound the balance between production and degradation of molecules is lost and degradation plays too large a role. Kerecis helps wound regain balance and heal.